These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38700719)

  • 21. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
    Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
    Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amelioration of propionic acid-induced autism spectrum disorder in rats through dapagliflozin: The role of IGF-1/IGFBP-3 and the Nrf2 antioxidant pathway.
    Erdogan MA; Nesil P; Altuntas I; Sirin C; Uyanikgil Y; Erbas O
    Neuroscience; 2024 Aug; 554():16-25. PubMed ID: 39004410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk Among NLRP3 Inflammasome, ET
    Muhammad RN; Ahmed LA; Abdul Salam RM; Ahmed KA; Attia AS
    Neurotherapeutics; 2021 Oct; 18(4):2664-2681. PubMed ID: 34664178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
    Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2.
    Wei J; Tan F; Long X; Fang Q; Wang Y; Wang J; He J; Yuan X; Du J
    Eur J Pharm Sci; 2023 Oct; 189():106531. PubMed ID: 37479045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
    Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
    Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model.
    Saleh S; Hanna G; El-Nabi SH; El-Domiaty H; Shabaan A; Fayez Ewida S
    J Genet; 2020; 99():. PubMed ID: 32529989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
    Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
    Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
    Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
    Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.
    Abdollahi E; Keyhanfar F; Delbandi AA; Falak R; Hajimiresmaiel SJ; Shafiei M
    Eur J Pharmacol; 2022 Mar; 918():174715. PubMed ID: 35026193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
    Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
    FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
    So EC; Liu PY; Wu SN
    Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.